Acupuncture for Hot Flashes in Hormone Receptor-Positive Breast Cancer, a Randomized Controlled Trial
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03783546 |
Recruitment Status :
Active, not recruiting
First Posted : December 21, 2018
Last Update Posted : March 19, 2024
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Breast Cancer | Device: Acupuncture Other: Usual Care | Not Applicable |
Hot flashes are a sensation of sudden onset of body warmth, flushing and sweating. Hot flashes are common side effects of breast cancer treatments and can affect mood and daily life. Medications can help ease hot flashes, but many patients continue to experience symptoms despite these treatments.
Acupuncture is a complementary therapy in which, hair-thin, sterile disposable needles are inserted into various spots on the skin, with the goal of affecting body's natural healing system. Acupuncture has been tested in clinical trials in cancer patients and has been shown to be helpful in treating a number of side effects of cancer treatment, such as nausea and vomiting from chemotherapy. A few early studies have suggested that acupuncture may help to lessen hot flashes, but more information is needed about the benefits of acupuncture in breast cancer patients.
This study is being done to test whether acupuncture can help to reduce the number and intensity of hot flashes in breast cancer patients who are being treated with mediations such as tamoxifen and aromatase inhibitors, such as anastrozole (Arimidex), exemestane (Aromasin), and letrozole (Femara).
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 80 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Supportive Care |
Official Title: | Acupuncture for Hot Flashes in Hormone Receptor-Positive Breast Cancer, a Randomized Controlled Trial |
Actual Study Start Date : | January 15, 2019 |
Actual Primary Completion Date : | February 28, 2022 |
Estimated Study Completion Date : | December 1, 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: Immediate Acupuncture
|
Device: Acupuncture
Acupuncture is a complementary therapy in which, hair-thin, sterile disposable needles are inserted into various spots on your skin, with the goal of affecting body's natural healing system |
Active Comparator: Delayed acupuncture
|
Other: Usual Care
the current standard of care with non-hormonal pharmacotherapy of western medicine |
- Change from baseline in mean weekly HFS score between acupuncture and usual care arms at the end of week 10 [ Time Frame: 10 weeks ]
- Response Rate [ Time Frame: 10 weeks ]
- Changes in the total and subscores in Functional Assessment of Cancer Therapy- Breast Cancer [ Time Frame: 2 years ]
- Changes in the total and subscores in Functional Assessment of Cancer Therapy- Endocrine Subscale [ Time Frame: 2 years ]
- Pittsburgh Sleep Quality Index [ Time Frame: 2 years ]
- Changes in plasma proinflammatory cytokines [ Time Frame: 2 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- History of histologically or cytologically proven Stage I-III breast cancer with estrogen receptor positive with HER-2 positive or negative tumor;
- Premenopausal or postmenopausal status;
- Completed all primary chemotherapy and surgery;
- Currently undergoing adjuvant hormonal therapy (e.g. Tamoxifen and/or Aromatase inhibitors) with or without ovarian function suppression for at least 4 weeks at study entry; the use of Trastuzumab after adjuvant chemotherapy is allowed;
- Reported persistent hot flashes for at least 4 weeks AND more than 14 episodes of hot flashes per week (2 hot flashes per day) during the week prior to the study entry;
- Age ≥ 18 years;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- Signed informed consent
Exclusion Criteria:
Undergoing chemotherapy or planned surgery, chemotherapy, change doses and regimen of hormonal therapy during the study period;
- Unstable cardiac disease or myocardial infarction within 6 months prior to study entry;
- Uncontrolled seizure disorder or history of seizure;
- Active clinically significant uncontrolled infection;
- Use of acupuncture for hot flashes within 6 months prior to the study entry;
- Uncontrolled major psychiatric disorders, such as major depression or psychosis;
- Newly starting pharmacologic treatment of hot flashes such as selective serotonin reuptake inhibitors (SSRIs) and/or anti-convulsant for less than 4 weeks prior to study entry. Participants may continue with medications or therapies for the treatment of hot-flashes while participating in the study if the medication has been taking for more than 4 weeks prior to study entry AND the dose of the medication is going to be kept consistently during the study
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03783546
United States, Massachusetts | |
Dana Farber Cancer Institute | |
Boston, Massachusetts, United States, 02215 |
Principal Investigator: | Weidong Lu, PhD, MPH | Dana-Farber Cancer Institute |
Responsible Party: | Weidong Lu, MB, MPH, PhD, Principal Investigator, Dana-Farber Cancer Institute |
ClinicalTrials.gov Identifier: | NCT03783546 |
Other Study ID Numbers: |
18-371 |
First Posted: | December 21, 2018 Key Record Dates |
Last Update Posted: | March 19, 2024 |
Last Verified: | March 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor- Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research. |
Time Frame: | Data can be shared no earlier than 1 year following the date of publication. |
Access Criteria: | Requests may be directed to: [contact information for Sponsor- Investigator or designee]. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Product Manufactured in and Exported from the U.S.: | No |
Breast Cancer |
Breast Neoplasms Hot Flashes Neoplasms by Site |
Neoplasms Breast Diseases Skin Diseases |